The Sentinel Registry

Last updated: June 11, 2025
Sponsor: Duk-Woo Park, MD
Overall Status: Completed

Phase

N/A

Condition

Heart Valve Disease

Treatment

Sentinel

Clinical Study ID

NCT05217888
AMCCV 2022-01
  • Ages > 19
  • All Genders

Study Summary

This registry is to evaluate procedural outcomes and safety outcomes of cerebral protection devices during transfemoral TAVR in real-world clinical practice.

The data from this registry will be compared with the extracted data from the TP TAVR registry(NCT038262664) using Propensity Score Matching.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 19 and more

  • Undergoing TAVR with the use of SENTINEL embolic protection device

  • Higher risk of cerebrovascular embolic events (any of the followings)

  1. Bicuspid aortic valve

  2. Calcified lesion or atherosclerosis in the ascending aorta and/or aortic arch

  3. Heavy calcified aortic valve (Ca. volume > 500)

  4. Chronic kidney disease

  5. Prior stroke

  6. Stroke risk is strongly anticipated by attending physicians

  • Compatible carotid and brachiocephalic artery anatomy for SENTINEL device asdetermined by Multi-Slice Computed Tomography scan or equivalent imaging modality

  • Agrees to the study protocol and the schedule of clinical follow-up and providesinformed, written consent, as approved by the appropriate Institutional ReviewBoard/Ethical Committee of the respective clinical site.

Exclusion

Exclusion Criteria:

  • Vasculature in the right extremity precluding radial or brachial access

  • Excessive tortuosity in the right radial/brachial/subclavian artery preventingSentinel System access and insertion

  • Inadequate circulation to the right extremity as evidenced by signs of arteryocclusion (modified Allen's test) or absence of radial/brachial pulse

  • Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremityvasculature

  • Symptomatic or asymptomatic severe occlusive carotid disease requiring concomitantcarotid endarterectomy/stenting

  • Undergone carotid stenting or carotid endarterectomy within the previous 6 weeks

  • Concurrent medical condition with a life expectancy of less than 1 year

Study Design

Total Participants: 158
Treatment Group(s): 1
Primary Treatment: Sentinel
Phase:
Study Start date:
May 18, 2022
Estimated Completion Date:
May 20, 2025

Connect with a study center

  • Bucheon Sejong Hospital

    Bucheon,
    Korea, Republic of

    Site Not Available

  • Keimyung University Dongsan Medical Center

    Daegu,
    Korea, Republic of

    Site Not Available

  • Chonnam National University Hospital

    Gwangju,
    Korea, Republic of

    Site Not Available

  • Bundang CHA Hospital

    Seongnam,
    Korea, Republic of

    Site Not Available

  • Seoul university Bundang hospital

    Seongnam-si,
    Korea, Republic of

    Site Not Available

  • Asan Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Korea University Anam Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Samsung medical center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Severance Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Pusan National University Yangsan Hospital

    Yangsan,
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.